The FDA has approved the first ready-to-use liquid formulation of topiramate (Eprontia oral solution) for partial-onset, primary generalized tonic-clonic seizures. Eprontia is indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age or older; adjunctive therapy for the treatment of partial-onset seizures, partial generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older; and preventive treatment of migraine in patients 12 years of age and older.
Eprontia is a product of Azurity Pharmaceuticals. It is a ready-to-use solution for oral administration containing 25 mg/mL of topiramate. Consult package labeling for prescribing information.
